Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC ...

Fred Alger Management, an investment management company, released its “Alger Mid Cap Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter of 2026 ...

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the ...

NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...

Avitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which ...

View Repligen Corporation RGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into ...

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty ...

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% ...

Smaller players in the life sciences industry are being scooped up. Repligen has masterfully done this to grow and stay competitive. The strategy has left some baggage on its financial statements.

Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's ...